Elias Jabbour Selected Research

bcr-abl Fusion Proteins

1/2022	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
1/2020	Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
12/2013	A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
4/2012	Treatment options for chronic myeloid leukemia.
6/2010	Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
1/2009	Treatment selection after imatinib resistance in chronic myeloid leukemia.
1/2009	Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
7/2008	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
5/2008	Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
3/2008	Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elias Jabbour Research Topics

Disease

115	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2022 - 01/2006
98	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 03/2006
92	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2022 - 08/2006
57	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 12/2005
56	Philadelphia Chromosome 05/2022 - 05/2007
53	Neoplasms (Cancer) 11/2022 - 11/2004
45	Leukemia 09/2022 - 11/2005
18	Residual Neoplasm 01/2021 - 12/2013
15	Blast Crisis (Blast Phase) 01/2021 - 01/2006
13	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2010
12	Disease Progression 05/2022 - 06/2005
12	Myeloid Leukemia (Leukemia, Myelocytic) 01/2021 - 11/2006
11	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 07/2011
11	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 10/2006
11	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 11/2004
10	Exanthema (Rash) 01/2021 - 05/2009
8	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 02/2006
7	Anemia 01/2022 - 07/2013
6	Infections 01/2022 - 05/2012
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 06/2012
6	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021 - 06/2015
6	Fatigue 01/2021 - 03/2008
6	Lymphoma (Lymphomas) 01/2021 - 06/2012
6	Neutropenia 01/2021 - 11/2012
6	Pathologic Complete Response 07/2020 - 05/2015
5	Hypertension (High Blood Pressure) 12/2020 - 11/2015
5	Nausea 09/2018 - 02/2015
4	Pneumonia (Pneumonitis) 01/2022 - 11/2012
4	Acute Promyelocytic Leukemia 01/2022 - 01/2017
4	Hemorrhage 12/2018 - 07/2010
4	Febrile Neutropenia 01/2018 - 11/2012
4	Drug-Related Side Effects and Adverse Reactions 06/2011 - 06/2010
3	Hyperbilirubinemia 01/2022 - 11/2017
3	Myocardial Infarction 12/2018 - 10/2007
3	Aplastic Anemia (Anemia, Hypoplastic) 11/2018 - 05/2012
3	Mucositis 10/2017 - 06/2015
3	Refractory Anemia with Excess of Blasts (RAEM) 04/2016 - 10/2013

Drug/Important Bio-Agent (IBA)

85	Tyrosine Kinase InhibitorsIBA 11/2022 - 11/2006
64	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 01/2006
33	Dasatinib (BMS 354825)FDA Link 05/2022 - 11/2006
29	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022 - 08/2005
24	Decitabine FDA Link 01/2021 - 12/2005
22	Inotuzumab OzogamicinIBA 01/2022 - 08/2013
20	nilotinib FDA Link 01/2018 - 11/2006
19	Pharmaceutical PreparationsIBA 01/2021 - 12/2005
18	venetoclaxIBA 11/2022 - 01/2018
17	ponatinibIBA 09/2022 - 04/2015
15	Azacitidine (5 Azacytidine)FDA Link 11/2021 - 12/2005
15	Clofarabine (Clolar)FDA Link 01/2021 - 07/2009
15	Phosphotransferases (Kinase)IBA 06/2018 - 08/2006
13	bcr-abl Fusion ProteinsIBA 01/2022 - 07/2007
11	blinatumomabIBA 01/2022 - 01/2017
11	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 10/2010
11	Monoclonal AntibodiesIBA 01/2021 - 09/2012
9	ruxolitinibIBA 11/2021 - 08/2012
9	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 03/2011
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2004
7	Rituximab (Mabthera)FDA Link 12/2021 - 10/2010
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 10/2010
7	fludarabineIBA 12/2021 - 08/2010
7	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021 - 01/2009
7	Dexamethasone (Maxidex)FDA LinkGeneric 10/2021 - 10/2010
6	fms-Like Tyrosine Kinase 3IBA 01/2022 - 11/2016
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 10/2010
6	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 08/2010
6	Transaminases (Aminotransferases)IBA 12/2018 - 04/2012
5	Prednisone (Sone)FDA LinkGeneric 12/2018 - 07/2011
5	BilirubinIBA 12/2018 - 04/2012
5	Gemtuzumab (Mylotarg)FDA Link 02/2017 - 04/2009
4	Cladribine FDA LinkGeneric 11/2022 - 08/2005
4	CreatinineIBA 01/2022 - 12/2018
4	InterferonsIBA 01/2021 - 08/2011
4	NucleophosminIBA 01/2021 - 08/2013
4	MethyltransferasesIBA 01/2021 - 05/2011
4	Hemoglobins (Hemoglobin)IBA 01/2021 - 03/2008
4	Lenalidomide (CC 5013)FDA Link 01/2021 - 07/2011
4	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 05/2011
4	guadecitabineIBA 06/2019 - 09/2015
4	Methotrexate (Mexate)FDA LinkGeneric 02/2016 - 04/2007
4	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 06/2005
3	ibrutinibIBA 12/2021 - 01/2019
3	eltrombopag FDA Link 11/2021 - 07/2010
3	bosutinibIBA 01/2021 - 05/2011
3	nelarabine (506U78)FDA Link 01/2021 - 01/2018
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 01/2017
3	HomoharringtonineIBA 01/2019 - 01/2015
3	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 01/2017
3	vosaroxinIBA 11/2018 - 09/2015
3	Purine NucleosidesIBA 01/2018 - 02/2014

Therapy/Procedure

149	Therapeutics 11/2022 - 06/2005
52	Drug Therapy (Chemotherapy) 05/2022 - 02/2006
21	Stem Cell Transplantation 07/2020 - 08/2006
11	Salvage Therapy 01/2022 - 07/2009
9	Hematopoietic Stem Cell Transplantation 01/2020 - 07/2007
7	Induction Chemotherapy 01/2022 - 08/2010
6	Transplantation 05/2022 - 10/2007
5	Immunotherapy 01/2022 - 12/2016
4	Cell Transplantation 01/2022 - 10/2020
3	Drug Tapering 11/2021 - 01/2018
3	Consolidation Chemotherapy 05/2020 - 01/2018